Bomze et al. found a significant association between tumor mutational burden (TMB) and immune-related adverse events (irAEs) across different cancer types during nivolumab or pembrolizumab anti-programmed cell death-1 (anti-PD-1) therapy [1]. This evidence concerns the gene PDCD1 and cancer.